Artivion Past Earnings Performance
Past criteria checks 0/6
Artivion's earnings have been declining at an average annual rate of -46.5%, while the Medical Equipment industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 5.8% per year.
Key information
-46.5%
Earnings growth rate
-45.2%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 5.8% |
Return on equity | -10.9% |
Net Margin | -8.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Artivion (NYSE:AORT) Using Too Much Debt?
Jan 13Artivion Stock: A First Assessment
Dec 27Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump
Nov 23Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025
Oct 13Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)
Jul 20Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 10Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet
Mar 09Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M
Feb 16Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold
Dec 18Artivion (NYSE:AORT) Is Making Moderate Use Of Debt
Sep 29Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver
Sep 27Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M
Aug 04Is Artivion (NYSE:AORT) Using Too Much Debt?
Jun 27Is Artivion (NYSE:AORT) Using Too Much Debt?
Mar 25CryoLife (NYSE:CRY) Has A Somewhat Strained Balance Sheet
Dec 08CryoLife, Inc. (NYSE:CRY) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 01CryoLife (NYSE:CRY) Takes On Some Risk With Its Use Of Debt
Jul 30Revenue & Expenses BreakdownBeta
How Artivion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 354 | -31 | 185 | 29 |
30 Sep 23 | 340 | -24 | 180 | 29 |
30 Jun 23 | 329 | -28 | 175 | 35 |
31 Mar 23 | 320 | -29 | 171 | 36 |
31 Dec 22 | 314 | -19 | 166 | 39 |
30 Sep 22 | 314 | -41 | 170 | 40 |
30 Jun 22 | 309 | -17 | 168 | 38 |
31 Mar 22 | 305 | -15 | 163 | 38 |
31 Dec 21 | 299 | -15 | 161 | 36 |
30 Sep 21 | 287 | 2 | 145 | 33 |
30 Jun 21 | 280 | -12 | 141 | 28 |
31 Mar 21 | 258 | -13 | 135 | 26 |
31 Dec 20 | 253 | -17 | 137 | 24 |
30 Sep 20 | 255 | -14 | 143 | 23 |
30 Jun 20 | 258 | -11 | 143 | 23 |
31 Mar 20 | 275 | -5 | 145 | 24 |
31 Dec 19 | 276 | 2 | 143 | 23 |
30 Sep 19 | 274 | 2 | 148 | 24 |
30 Jun 19 | 271 | 3 | 140 | 23 |
31 Mar 19 | 268 | 1 | 140 | 23 |
31 Dec 18 | 263 | -3 | 141 | 23 |
30 Sep 18 | 248 | -5 | 128 | 23 |
30 Jun 18 | 227 | -5 | 127 | 22 |
31 Mar 18 | 207 | -2 | 116 | 21 |
31 Dec 17 | 190 | 4 | 101 | 19 |
30 Sep 17 | 182 | 9 | 100 | 17 |
30 Jun 17 | 183 | 11 | 96 | 16 |
31 Mar 17 | 182 | 10 | 94 | 15 |
31 Dec 16 | 180 | 11 | 92 | 13 |
30 Sep 16 | 175 | 10 | 78 | 12 |
30 Jun 16 | 167 | 9 | 76 | 11 |
31 Mar 16 | 155 | 7 | 74 | 11 |
31 Dec 15 | 146 | 4 | 72 | 10 |
30 Sep 15 | 143 | 3 | 74 | 10 |
30 Jun 15 | 144 | 3 | 76 | 9 |
31 Mar 15 | 143 | 6 | 74 | 8 |
31 Dec 14 | 145 | 7 | 74 | 9 |
30 Sep 14 | 142 | 14 | 72 | 9 |
30 Jun 14 | 141 | 15 | 69 | 9 |
31 Mar 14 | 140 | 15 | 68 | 9 |
31 Dec 13 | 141 | 16 | 68 | 8 |
30 Sep 13 | 138 | 9 | 68 | 8 |
30 Jun 13 | 135 | 7 | 68 | 8 |
31 Mar 13 | 135 | 9 | 67 | 8 |
Quality Earnings: AORT is currently unprofitable.
Growing Profit Margin: AORT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AORT is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.
Accelerating Growth: Unable to compare AORT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AORT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.7%).
Return on Equity
High ROE: AORT has a negative Return on Equity (-10.89%), as it is currently unprofitable.